While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

After Merck KGaA's recent confirmation that it's in "advanced discussions" to acquire SpringWorks Therapeutics, the Connecticut rare disease specialist has boosted its value with a new FDA nod.

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

One of the most significant developments for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as strategically sound for ...

Notably, there has been speculation about a potential acquisition of SpringWorks by Merck (NSE:PROR) KGaA. Analysts view this potential acquisition as strategically sound for several reasons: 1. There ...